{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:42:36Z","timestamp":1786650156781,"version":"build-2736575974"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>The diagnosis and management of polypoidal choroidal vasculopathy (PCV), a complex chorioretinal disease which constitutes 60% of neovascular age-related macular degeneration cases among Asians, have evolved significantly in the last decade. SD-OCT biomarkers can reliably diagnose and monitor PCV, restricting the role of invasive indocyanine green angiography to situations like suboptimal responders to therapy where it helps to clarify the diagnosis and explore other treatment options like laser. The introduction of Aflibercept resulted in a paradigm shift in the treatment from combination therapy (photodynamic therapy plus injection of anti-VEGF drugs) to anti-VEGF monotherapy after it was proven noninferior to the former in the PLANET trial. The limited availability of PDT also favored this shift. The longer half-life of Aflibercept led to adoption of proactive treatment regimens like treat and extend guided by fluid markers on OCT, reducing the treatment burden. Newer molecules with more potency and durability like Brolucizumab and Faricimab demonstrated superior drying effects and achieved a longer treatment interval of up to 16 weeks, offering additional options for anti-VEGF monotherapy. HAWK and HARRIER trials proved the noninferiority of Brolucizumab to Aflibercept, though there were safety concerns of inflammation. Interim analysis of the on-going SALWEEN trial for Faricimab in PCV has also shown favorable outcomes. Characterizing the different phenotypes of PCV based on OCT and choosing the appropriate drug and treatment regimen are important to maximize visual outcome while reducing the treatment burden. This article reviews the evolution of anti-VEGF therapy in PCV and provides recommendations for optimal management in the real world.<\/jats:p>","DOI":"10.4103\/ijo.ijo_3237_25","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:01:22Z","timestamp":1777478482000},"page":"669-680","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy"],"prefix":"10.4103","volume":"74","author":[{"given":"Anantharaman","family":"Giridhar","sequence":"first","affiliation":[{"name":"Department of Vitreo-Retina, Giridhar Eye Institute, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Lekha","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retina, Giridhar Eye Institute, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Chandran","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retina, Giridhar Eye Institute, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"R1-20260514","first-page":"527","article-title":"Anti-VEGF therapy for neovascular AMD and polypoidal choroidal vasculopathy","volume":"6","author":"Cheung","year":"2017","journal-title":"Asia Pac J Ophthalmol"},{"key":"R2-20260514","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: A randomized clinical trial","volume":"135","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R3-20260514","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.4103\/ijo.IJO_1222_17","article-title":"Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy","volume":"66","author":"Jain","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"R4-20260514","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3341\/kjo.2023.0145","article-title":"Efficacy of brolucizumab in polyp regression of treatment-naive polypoidal choroidal vasculopathy and its effect on 1-year treatment outcome","volume":"38","author":"Lee","year":"2024","journal-title":"Korean J Ophthalmol"},{"key":"R5-20260514","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: A randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R6-20260514","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3390\/jcm4050782","article-title":"Polypoidal choroidal vasculopathy in Asians","volume":"4","author":"Wong","year":"2015","journal-title":"J Clin Med"},{"key":"R7-20260514","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41433-023-02764-w","article-title":"Macular neovascularization and polypoidal choroidal vasculopathy: Phenotypic variations, pathogenic mechanisms and implications in management","volume":"38","author":"Cheung","year":"2024","journal-title":"Eye"},{"key":"R8-20260514","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000548709","article-title":"Polypoidal choroidal vasculopathy: From clinicopathological and molecular perspectives","volume":"68","author":"Zhang","year":"2025","journal-title":"Ophthalmic Res"},{"key":"R9-20260514","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/APO.0000000000000577","article-title":"Plasma cytokine profiles in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration","volume":"11","author":"Zhou","year":"2022","journal-title":"Asia Pac J Ophthalmol"},{"key":"R10-20260514","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: Definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"key":"R11-20260514","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.oret.2018.08.008","article-title":"Clinicopathologic correlation of aneurysmal type 1 neovascularization in age-related macular degeneration","volume":"3","author":"Li","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"R12-20260514","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.oret.2023.11.001","article-title":"Polypoidal choroidal vasculopathy: Evaluation based on 3-dimensional reconstruction of OCT angiography","volume":"8","author":"Teo","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"R13-20260514","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1016\/j.ajpath.2017.08.025","article-title":"Proteolytic degradation and inflammation play critical roles in polypoidal choroidal vasculopathy","volume":"187","author":"Kumar","year":"2017","journal-title":"Am J Pathol"},{"key":"R14-20260514","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4103\/ijo.IJO_1136_17","article-title":"Polypoidal choroidal vasculopathy: Pearls in diagnosis and management","volume":"66","author":"Anantharaman","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"R15-20260514","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.4103\/ijo.IJO_2985_21","article-title":"Updated guidelines for the management of polypoidal choroidal vasculopathy: Recommendations from the Indian polypoidal choroidal vasculopathy panel and the Vitreoretinal Society of India","volume":"70","author":"Sheth","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"R16-20260514","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ajoc.2018.01.031","article-title":"Management of recalcitrant polypoidal choroidal vasculopathy by feeder vessel laser photocoagulation","volume":"9","author":"Sheth","year":"2018","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R17-20260514","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1167\/iovs.62.2.29","article-title":"Choroidal vascular abnormalities by ultra-widefield indocyanine green angiography in polypoidal choroidal vasculopathy","volume":"62","author":"Jeong","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R18-20260514","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","article-title":"Polypoidal choroidal vasculopathy: Consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV workgroup","volume":"128","author":"Cheung","year":"2021","journal-title":"Ophthalmology"},{"key":"R19-20260514","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.oret.2021.04.002","article-title":"Non-ICGA treatment criteria for Suboptimal Anti-VEGF response for polypoidal choroidal vasculopathy: APOIS PCV workgroup report 2","volume":"5","author":"Teo","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"R20-20260514","first-page":"165","article-title":"New concepts in polypoidal choroidal vasculopathy imaging: A focus on optical coherence tomography and optical coherence tomography angiography","volume":"8","author":"Teo","year":"2019","journal-title":"Asia Pac J Ophthalmol"},{"key":"R21-20260514","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41433-021-01688-7","article-title":"Evolving treatment paradigms for PCV","volume":"36","author":"Fenner","year":"2022","journal-title":"Eye"},{"key":"R22-20260514","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.ophtha.2003.12.056","article-title":"Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: One-year results of a prospective case series","volume":"111","author":"Chan","year":"2004","journal-title":"Ophthalmology"},{"key":"R23-20260514","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00417-005-1139-4","article-title":"Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin","volume":"243","author":"Silva","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R24-20260514","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/eye.2008.265","article-title":"Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy","volume":"23","author":"Lee","year":"2009","journal-title":"Eye"},{"key":"R25-20260514","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12886-020-01419-8","article-title":"Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy","volume":"20","author":"Ngo","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"R26-20260514","first-page":"615","article-title":"Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration","volume":"7","author":"Tsuchihashi","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"R27-20260514","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.tjo.2012.04.004","article-title":"Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy treatment: 3-year results in Taiwan","volume":"2","author":"Lee","year":"2012","journal-title":"Taiwan J Ophthalmol"},{"key":"R28-20260514","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1097\/IAE.0000000000001427","article-title":"Choroidal thickness as a prognostic factor of photodynamic therapy with aflibercept or ranibizumab for polypoidal choroidal vasculopathy","volume":"37","author":"Sakurada","year":"2017","journal-title":"Retina"},{"key":"R29-20260514","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.4103\/ijo.IJO_975_18","article-title":"Current management strategy of polypoidal choroidal vasculopathy","volume":"66","author":"Ho","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"R30-20260514","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/IAE.0b013e3182852446","article-title":"Polypoidal choroidal vasculopathy: Evidence-based guidelines for clinical diagnosis and treatment","volume":"33","author":"Chen","year":"2013","journal-title":"Retina"},{"key":"R31-20260514","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: The EVEREST II randomized clinical trial","volume":"138","author":"Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R32-20260514","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.ophtha.2013.12.037","article-title":"LAPTOP study: A 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy","volume":"121","author":"Oishi","year":"2014","journal-title":"Ophthalmology"},{"key":"R33-20260514","doi-asserted-by":"crossref","first-page":"20115","DOI":"10.1038\/s41598-021-99634-w","article-title":"Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy","volume":"11","author":"Ma","year":"2021","journal-title":"Sci Rep"},{"key":"R34-20260514","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4103\/0301-4738.36473","article-title":"Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration","volume":"55","author":"Kim","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"R35-20260514","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: Two-year results of the aflibercept in polypoidal choroidal vasculopathy study","volume":"204","author":"Wong","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R36-20260514","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/APO.0000000000000445","article-title":"Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: Consensus and recommendations from the Asia-Pacific Vitreo-retina Society","volume":"10","author":"Chaikitmongkol","year":"2021","journal-title":"Asia Pac J Ophthalmol"},{"key":"R37-20260514","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1007\/s12325-022-02162-w","article-title":"Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in the ALTAIR Study: 96-week outcomes in the polypoidal choroidal vasculopathy subgroup","volume":"39","author":"Okada","year":"2022","journal-title":"Adv Ther"},{"key":"R38-20260514","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.oret.2020.03.010","article-title":"Two-year outcomes of treat-and-extend intravitreal aflibercept for exudative age-related macular degeneration: A prospective study","volume":"4","author":"Maruko","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R39-20260514","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/bjophthalmol-2020-318354","article-title":"Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy","volume":"106","author":"Teo","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R40-20260514","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40123-023-00850-6","article-title":"Two-year real-world results for aflibercept using the treat-and-extend regimen in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy","volume":"13","author":"Huang","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"R41-20260514","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000533529","article-title":"Anti-vascular endothelial growth factor therapy regimens for polypoidal choroidal vasculopathy: A systematic review","volume":"246","author":"Mihalache","year":"2023","journal-title":"Ophthalmologica"},{"key":"R42-20260514","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, Multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"R43-20260514","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: Ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"R44-20260514","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1136\/bjophthalmol-2021-319090","article-title":"Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK","volume":"106","author":"Ogura","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R45-20260514","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1177\/11206721211059332","article-title":"Ocular adverse events following intravitreal brolucizumab for neovascular age-related macular degeneration at a single tertiary care center","volume":"32","author":"Nguyen","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"R46-20260514","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: Post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"key":"R47-20260514","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1038\/s41598-022-12216-2","article-title":"One-year outcomes of intravitreal brolucizumab injections in patients with polypoidal choroidal vasculopathy","volume":"12","author":"Ito","year":"2022","journal-title":"Sci Rep"},{"key":"R48-20260514","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1089\/jop.2023.0030","article-title":"Intravitreal brolucizumab and aflibercept for polypoidal choroidal vasculopathy","volume":"39","author":"Cho","year":"2023","journal-title":"J Ocul Pharmacol Ther"},{"key":"R49-20260514","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00417-022-05793-5","article-title":"Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: An 18-month follow-up study","volume":"261","author":"Ueda-Consolvo","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R50-20260514","doi-asserted-by":"crossref","first-page":"e42666","DOI":"10.1097\/MD.0000000000042666","article-title":"Usage of brolucizumab as treatment for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV): A narrative review","volume":"104","author":"Jezani","year":"2025","journal-title":"Medicine"},{"key":"R51-20260514","doi-asserted-by":"crossref","first-page":"156","DOI":"10.21561\/jor.2024.9.2.156","article-title":"Clinical outcomes of switching to brolucizumab in refractory polypoidal choroidal vasculopathy treated with aflibercept","volume":"9","author":"Baek","year":"2024","journal-title":"J Retin"},{"key":"R52-20260514","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: Two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"R53-20260514","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.2147\/OPTH.S527787","article-title":"Switching to faricimab for polypoidal choroidal vasculopathy with real-world outcomes in refractory cases - The FAR-PEARL study report 1","volume":"19","author":"Fong","year":"2025","journal-title":"Clin Ophthalmol"},{"key":"R55-20260514","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/aos.16797","article-title":"Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: A systematic review and meta-analysis","volume":"103","author":"Arnold-Vangsted","year":"2025","journal-title":"Acta Ophthalmol"},{"key":"R56-20260514","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40123-024-00888-0","article-title":"Six-year outcomes in subjects with polypoidal choroidal vasculopathy in the EVEREST II study","volume":"13","author":"Teo","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"R57-20260514","doi-asserted-by":"crossref","first-page":"e1579","DOI":"10.1111\/aos.15149","article-title":"Comparison of visual outcomes of polypoidal choroidal vasculopathy and typical neovascular age-related macular degeneration-up to 10 years of follow-up","volume":"100","author":"Park","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"R58-20260514","doi-asserted-by":"crossref","first-page":"100759","DOI":"10.1016\/j.xops.2025.100759","article-title":"Sozinibercept (Anti-VEGF-C\/-D) combined with ranibizumab for polypoidal choroidal vasculopathy: Phase IIb predefined subgroup analysis","volume":"5","author":"Cheung","year":"2025","journal-title":"Ophthalmol Sci"},{"key":"R59-20260514","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet"},{"key":"R60-20260514","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jamaophthalmol.2025.5098","article-title":"Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial","volume":"144","author":"Lee","year":"2026","journal-title":"JAMA Ophthalmol"},{"key":"R61-20260514","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4103\/IJO.IJO_927_25","article-title":"Management of polypoidal choroidal vasculopathy and diabetic retinopathy: Practice patterns amongst vitreoretinal surgeons of India-A VRSI survey","volume":"73","author":"Sindal","year":"2025","journal-title":"Indian J Ophthalmol"},{"key":"R62-20260514","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/APO.0000000000000551","article-title":"Optical coherence tomography features for identifying posttreatment complete polypoidal regression in polypoidal choroidal vasculopathy","volume":"11","author":"Chaikitmongkol","year":"2022","journal-title":"Asia Pac J Ophthalmol"},{"key":"R63-20260514","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.3390\/jcm10245739","article-title":"Short-term outcomes of switching to ranibizumab in polypoidal choroidal vasculopathy resistant to aflibercept therapy","volume":"10","author":"Jeon","year":"2021","journal-title":"J Clin Med"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3237_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:04:48Z","timestamp":1786647888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3237_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3237_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2025-12-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}